New Start in 2025 | Shanghai Hycells Biotechnology and Shandong Qidu Biotechnology Sign Strategic Cooperation Agreement
Release Date:
2025-01-21 14:53
New Start in 2025
On January 18, 2025, Shanghai Hycells Biotechnology and Shandong Qidu Biotechnology signed a strategic cooperation agreement to jointly pursue product development initiatives. Since its establishment, Hycells has been committed to providing customers with integrated solutions for the R&D, manufacturing, sales, and service of primary immune cell products. Leveraging cutting-edge biotechnology and a robust R&D team, and supported by its cell bank and culture media R&D platform, the company offers a comprehensive suite of customized services for immune cells, stem cells, and related cell culture media.
Shandong Qidu Biopharmaceutical Co., Ltd. is a biopharmaceutical company dedicated to the research and development of cutting-edge biopharmaceutical technologies and products, renowned throughout the industry for its superior product quality and strong market competitiveness. The company has established the Zibo City Cell Medicine Engineering Technology Research Center, which includes a high-standard, over-1,000-square-meter cell medicine cleanroom and a production line capable of manufacturing 5 million vials of high-end liquid culture media annually. It has thus developed three core technology platforms: a liquid culture media R&D platform, a cell medicine research platform, and an in vitro diagnostic reagent technology platform for self-testing systems.
Immune cell and stem cell culture media are indispensable critical raw materials in biopharmaceutical manufacturing, and their quality and stability directly impact the quality and safety of the final product. To meet the growing market demand for high-quality immune cell culture media while enhancing the production efficiency and market competitiveness of both companies, Hycells Biotechnology and Shandong Qidu Biotechnology have decided to collaborate. Under the agreement, the two parties will engage in joint innovation in the field of immune cell and stem cell culture media, jointly pursue cutting-edge technologies, tackle key technological challenges through R&D, and deepen industry–university–research collaboration, thereby collectively advancing forward-looking technological planning and driving product transformation and upgrading. This collaboration aims to integrate the high-quality resources of both parties and leverage their respective strengths, thereby enhancing the production efficiency and market competitiveness of both companies and actively fostering the high-quality development of the biopharmaceutical industry.
Photo from the Signing and Exchange Ceremony
Looking ahead, Hycells Biotechnology and Shandong Qidu Biotechnology will continue to deepen their collaboration, expand into new areas of cooperation, and jointly explore new opportunities in the biopharmaceutical industry.
Mr. Ren, General Manager of Shandong Qidu Bio (far left), and Mr. Zhou, General Manager of Hycells Bio (far right)
Official Signing Ceremony
The cooperation signing ceremony has concluded, Mr. Ren, General Manager of Shandong Qidu Biopharmaceutical Co., Ltd., presented Hycells Bio with a special gift: a 2025 “Abundance Through the Four Seasons” display plate from Huaguang National Porcelain, symbolizing harmony among heaven, earth, and humanity and the enduring blessings of fortune and prosperity. Blessings to us, and blessings to you as well. The Snake Offers Rui Ruyi, spring sunshine shines; may your home be filled with harmony, prosperity, and good fortune in all four seasons!
The photo shows the scene of the “Blessings Abound in All Four Seasons” plating ceremony.
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board